Skip to main content
Lineage Cell Therapeutics Inc. logo

Lineage Cell Therapeutics Inc. — Investor Relations & Filings

Ticker · LCTX ISIN · US53566P1093 LEI · 5299002BI4W22SDF8R25 TA Manufacturing
Open in API
Filings indexed 2,777 across all filing types
Latest filing 2026-05-13 Interim / Quarterly Rep…
Country US United States of America
Listing TA LCTX

About Lineage Cell Therapeutics Inc.

https://lineagecell.com/

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel allogeneic cell therapies for unmet medical needs. The company's proprietary platform uses directed differentiation of pluripotent stem cells to manufacture specialized human cells. These "off-the-shelf" cell transplants are designed to replace or support dysfunctional cells in patients with serious conditions, aiming to restore or enhance physiological function. The therapeutic pipeline is focused on degenerative diseases of the eye, such as dry age-related macular degeneration, and neurological conditions, including spinal cord injury. The company leverages its integrated capabilities in cell line development, manufacturing, and delivery to advance its programs.

Recent filings

Filing Released Lang Actions
10-Q- First Quarter 2026 Financial Results
Interim / Quarterly Report Classification · 92% confidence The document is a U.S. SEC Form 10-Q for the quarterly period ended March 31, 2026. It contains unaudited condensed consolidated interim financial statements (balance sheets, statements of operations, cash flows, and notes) as well as MD&A, market risk disclosures, legal proceedings, and other quarterly disclosures. This matches the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-13 English
10-Q- First Quarter 2026 Financial Results
Report Publication Announcement Classification · 85% confidence The document is titled “QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934” but contains no actual financial statements or data—only a notice that the Form 10-Q is attached as a separate PDF. It is under 5,000 characters and follows the pattern of announcing publication of a report rather than providing the report content itself. Therefore, it qualifies as a Report Publication Announcement (Code: RPA).
2026-05-13 English
First Quarter 2026 Financial Results and Provides Business Update
Earnings Release Classification · 93% confidence The document is a press release titled “Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update.” It contains a summary of key clinical and corporate highlights, detailed Q1 financial metrics (revenues, operating expenses, net loss, balance sheet highlights), and conference call details. It is structured as an earnings announcement rather than a full interim regulatory report. Therefore, it fits the Earnings Release category. Q1 2026
2026-05-13 English
First Quarter 2026 Financial Results and Provides Business Update
Report Publication Announcement Classification · 93% confidence The document is an Immediate Report under Israeli regulations stating that the First Quarter 2026 Financial Results and Business Update report is attached as a PDF, without containing the financial results themselves. It is brief (2,041 characters) and functions solely to announce the publication of the report. Under the “Menu vs Meal” rule, this is a Report Publication Announcement, not the report itself.
2026-05-13 English
The company's financial results for the First quarter of 2026 were reported abroad
Report Publication Announcement Classification · 90% confidence The document is a very brief notice from the Tel Aviv Stock Exchange stating that Lineage Cell Therapeutics’ first quarter 2026 financial results “were reported abroad.” It contains no financial data itself and simply announces the publication of the quarter results, fitting the Report Publication Announcement category.
2026-05-13 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.